Ventripoint Diagnostics Issues Shares to Pay Debenture Interest
News related to:Ventripoint Diagnostics Ltd · 1 min read
Ventripoint Diagnostics Ltd, a company at the forefront of AI-driven echocardiography, has issued 601,115 common shares to settle $72,143 of interest on certain outstanding Convertible Debentures. The debentures, issued on May 10, June 28, and December 16, 2024, carry a 10% annual interest rate, payable every six months.
The shares were issued at a deemed price of $0.12 each, subject to a four-month hold period. The issuance does not create a control person for the company. The transaction is considered a related party transaction under TSXV Policy 5.9 and Multilateral Instrument 61-101 (MI-61-101), as certain insiders of the company will receive 48,383 common shares.
Ventripoint Diagnostics Ltd, based in Toronto, Ontario, has established itself as a leader in AI applications for echocardiography. Its VMS products, powered by proprietary knowledge-based reconstruction technology, offer accurate volumetric cardiac measurements equivalent to MRI. This technology provides cardiologists with a more reliable tool for patient management, making it an essential standard for the company's future developments.
The company's decision to issue shares for interest payment reflects its ongoing financial management practices. The issuance is subject to the approval of the TSX Venture Exchange and is exempt from the valuation and minority shareholder approval requirements of MI-61-101, as the fair market value of the insiders' participation does not exceed 25% of the company's market capitalization.
Ventripoint's commitment to innovation and patient care is evident in its product offerings and financial strategies. The company continues to navigate the complexities of the healthcare industry, ensuring that its solutions remain at the forefront of diagnostic technology.
The issuance of shares for interest payment is a routine financial transaction that aligns with the company's broader financial management strategy. It underscores Ventripoint's dedication to maintaining its financial health while continuing to invest in cutting-edge technology and research.